Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Watson Pharmaceuticals, a global specialty pharmaceutical company, has reported that its subsidiary Watson Laboratories has received approval from the FDA on its abbreviated new drug application (ANDA) for Metoprolol Succinate extended-release tablets USP in the 100 and 200 mg strengths.
Subscribe to our email newsletter
Metoprolol Succinate is a generic equivalent to AstraZeneca’s Toprol XL tablet. Metoprolol succinate extended-release is used to treat angina, heart failure and high blood pressure.
Metoprolol Succinate extended-release tablets are a beta-adrenergic blocking agent (beta-blocker). It works by reducing the amount of work the heart has to do (reduces chest pain) and the amount of blood the heart pumps out (lowers high blood pressure).
Additionally, it is also used to stabilize the heart rhythm in conditions in which the heart is beating too fast or in an irregular rhythm.